Clinical trial NCT06647563: Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Official title: A Randomized Controlled Study of Toripalimab Combined With Chemotherapy or With Chemotherapy/Cetuximab as Neoadjuvant Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Neo-ICT)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Squamous Cell Carcinoma of Head and Neck
Keywords: Programmed Cell Death-1 (PD1, PD-1)
Head and Neck Squamous Cell Carcinoma
Toripalimab
Albumin-bound paclitaxel
Carboplatin
Cetuximab
Neoadjuvant
Lead sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Sponsor class: OTHER
First posted: 2024-10-18
Enrollment: 355
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a randomized, active-controlled, open-label clinical trial for participants with newly diagnosed Stage III-IVb, resectable, locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). The study consists of two experimental arms and one control arm. Participants in Experimental Arm A will receive two cycles of Toripalimab, albumin-bound paclitaxel, carboplatin, and cetuximab prior to surgery. Participants in Experimental Arm B will receive two cycles of Toripalimab, albumin-bound paclitaxel, and carboplatin before surgical intervention. Following the surgical procedure, individuals in both Experimental Arm A and B will continue to receive 15 cycles of Toripalimab. The Control Arm will undergo the current standard treatment without preoperative drug intervention. Postoperatively, participants will be administered postoperative radiotherapy or chemoradiotherapy based on their recurrence risk. The primary study hypotheses are that the treatments in the Experimental Arms will improve the 2-year event-free survival (EFS) rates compared to the standard control treatment.


Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed squamous cell carcinoma of the head and neck (excluding nasopharyngeal cancer);
2. Male or female, aged 18-75 years;
3. Clinical stage III-IVb (AJCC 8th edition TNM stage) and operable patients; if oropharyngeal squamous cell carcinoma (P16-), the stage is III-IVb; if oropharyngeal squamous cell carcinoma (P16+), the stage is III;
4. No prior antitumor therapy including radiotherapy, chemotherapy, immunotherapy or biological therapy for the current tumor;
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1;
6. Life expectancy ≥ 6 months;
7. No obvious contraindications to immunotherapy, radiochemotherapy, or surgical treatment;
8. Willing to accept surgical treatment;
9. The level of main organ function meets the following criteria:

   1. Routine blood tests: WBC ≥ 4.0 × 10\^9/L, ANC ≥ 1.5 × 10\^9/L, PLT ≥ 100 × 10\^9/L, Hb ≥ 90 g/L (no blood transfusion or blood products within 14 days, no correction with G-CSF and other hematopoietic growth factors);
   2. Biochemical assessments: serum albumin ≥ 3.0 g/dL (30 g/L), TBIL ≤ 1.5 × ULN, ALT, AST ≤ 2.5 × ULN, BUN and CRE ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula);
   3. Adequate coagulation function: defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; If the subject is receiving anticoagulant therapy, PT should be within the proposed therapeutic range of the anticoagulant;
10. Women of childbearing potential must have a negative pregnancy test result (serum or urine), conducted within seven days prior to enrollment and agree to use effective contraception during the study period and for six months post last dose of anti-PD-1 antibody administration. Male subjects with female partners who are capable of conception must also utilize effective contraception throughout this study duration and for six months after their final dose anti-PD-1 antibody;
11. Willingness to participate in this study by signing an informed consent form, while exhibiting strong compliance and readiness to cooperate with follow-up procedures.

Exclusion Criteria:

1. Previous treatment with anti-PD-1/PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody, or other drugs/antibodies targeting T cell co-stimulation or checkpoint pathway;
2. Active autoimmune disease. Subjects in stable condition who do not require systemic immunosuppressive therapy are permitted; examples include type I diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, and skin conditions that do not necessitate systemic treatment (e.g., vitiligo, psoriasis, alopecia).
3. Patients with congenital or acquired immunodeficiency (e.g., HIV infection), active hepatitis B (HBV-DNA ≥ 10\^4 copies/ml) or hepatitis C (positive antibody for HCV, and HCV-RNA above the lower limit of detection of the analytical procedure);
4. Known allergy to the study drug or any of its excipients; or serious allergic reaction to other monoclonal antibodies.
5. The occurrence of any of the following conditions within 6 months prior to randomization: myocardial infarction, severe/unstable angina pectoris, NYHA class II or higher cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmias, and symptomatic congestive heart failure.
6. Vaccination with live vaccines within 4 weeks prior to the first dose of the study drug. Inactivated virus vaccine can be administered for seasonal flu, but not attenuated live influenza vaccines administered intranasally.
7. Known history of allogeneic organ transplant or allogeneic stem cell transplant.
8. The history of drug addiction and the abuse of psychoactive substances.
9. Pregnant or breastfeeding women.
10. Any other malignant neoplasm diagnosed within 5 years prior to study entry, except for carcinoma that is amenable to local treatment and has been cured, such as basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, carcinoma in situ of breast ductal, and papillary thyroid cancer.
11. Patients with other significant physical or mental health conditions, or laboratory test abnormalities that may elevate the risk of participation in the study or compromise the integrity of the study results, as determined by the investigators, are deemed unsuitable for participation in this study.

Primary outcomes:
measure: ICT vs Control: Two-Year Event-free Survival (EFS) rate
timeFrame: Up to ~72 months
measure: IC vs Control: Two-Year EFS rate
timeFrame: Up to ~72 months
Secondary outcomes:
measure: ICT vs Control: Overall Survival (OS)
timeFrame: Up to ~96 months
measure: IC vs Control: OS
timeFrame: Up to ~96 months
measure: ICT vs IC: Major Pathological Response (MPR)
timeFrame: Up to ~40 months
measure: ICT vs IC: Pathological Complete Response (PCR)
timeFrame: Up to ~40 months
measure: ICT vs IC: Objective Response Rate (ORR)
timeFrame: Up to ~40 months
measure: ICT vs Control: Three-Year EFS rate
timeFrame: Up to ~84 months
measure: ICT vs Control: Five-Year EFS rate
timeFrame: Up to ~96 months
measure: IC vs Control: Three-Year EFS rate
timeFrame: Up to ~84 months
measure: IC vs Control: Five-Year EFS rate
timeFrame: Up to ~96 months
measure: ICT vs IC: Two-Year EFS rate
timeFrame: Up to ~72 months
measure: ICT vs IC: Three-Year EFS rate
timeFrame: Up to ~84 months
measure: ICT vs IC: Five-Year EFS rate
timeFrame: Up to ~96 months
measure: ICT vs IC vs Control: Locoregional recurrence-free survival (LRFS) rate
timeFrame: Up to ~96 months
measure: ICT vs IC vs Control: Distant Disease-free Survival (DDFS) rate
timeFrame: Up to ~96 months
measure: ICT vs IC vs Control: Change From Baseline in Global Health Status/Quality of Life Scale (GHS/QoL)
timeFrame: Up to ~96 months
measure: ICT vs IC vs Control: Change From Baseline in Global Health Status/Physical Functioning Scales
timeFrame: Up to ~96 months
measure: ICT vs IC vs Control: Change from Baseline in Swallowing, Speech, and Pain Symptoms
timeFrame: Up to ~96 months
measure: ICT vs IC vs Control: Percentage of Participants Experiencing An Adverse Event (AEs)
timeFrame: Up to ~96 months
measure: ICT vs IC: Percentage of Participants Discontinuing Study Drug Due to AEs
timeFrame: Up to ~48 months
measure: ICT vs IC: OS
timeFrame: Up to ~96 months
Other outcomes:
Locations:
Study officials:
affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
name: Yue He, M.D.
role: PRINCIPAL_INVESTIGATOR
References: